Therapeutic area intelligence for Electrolyte Imbalance with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 4
Catalysts: 0
Companies: 1

Companies

Lupin →

Assets

Caplin →

FDA →

Recent signals(4)

RegulatoryAugust 3, 2026

FDA Grants Approval for Calcium Gluconate by Caplin

The FDA has granted approval for Calcium Gluconate under application ANDA218840 submitted by Caplin.

RegulatoryJuly 21, 2026

FDA Grants Approval for Lupin's Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride

The FDA has approved ANDA216095 for a combination product containing sodium sulfate, magnesium sulfate, and potassium chloride.

StrategyJuly 16, 2026

FDA Approves Original Application for Magnesium Sulfate by Square Pharms PLC

The FDA has approved the original application ANDA217461 for Magnesium Sulfate submitted by Square Pharms PLC.

RegulatoryJuly 12, 2026

FDA Accepts ANDA for Calcium Gluconate by Caplin

The FDA has accepted the Abbreviated New Drug Application (ANDA) for Calcium Gluconate submitted by Caplin.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.